Beta-endorphin
beta-endorphin(1-31), POMC-derived opioid peptide, beta-lipotropin(61-91)
Beta-endorphin is a 31-residue opioid peptide cleaved from proopiomelanocortin, the same precursor that yields ACTH and the melanocortins. It is a potent endogenous mu-opioid agonist and is co-released with ACTH from the pituitary during stress. It is central to the popular idea of the endorphin rush, though the human evidence is more nuanced than that phrase suggests.
Mechanism
Proopiomelanocortin is processed tissue-specifically: in the anterior pituitary it yields ACTH and beta-lipotropin, and in the intermediate lobe and hypothalamic arcuate neurons further cleavage of beta-lipotropin liberates beta-endorphin(1-31). The peptide is a high-affinity agonist at mu-opioid receptors, with meaningful delta activity and negligible kappa activity. Mu receptors are Gi/Go-coupled: they inhibit adenylate cyclase, open GIRK potassium channels and close N-type calcium channels, producing presynaptic inhibition of transmitter release and postsynaptic hyperpolarisation. Disinhibition of ventral tegmental dopamine neurons by suppressing GABAergic interneurons underlies the rewarding component.
Two anatomically separate pools matter and are frequently conflated. Pituitary beta-endorphin is secreted into the bloodstream with ACTH under corticotropin-releasing hormone drive and acts as a peripheral hormone; it crosses the blood-brain barrier poorly. Central beta-endorphin from arcuate neurons projects to the periaqueductal grey, amygdala, nucleus accumbens and hypothalamus and mediates stress-induced analgesia, reward and appetite regulation. Plasma concentrations therefore tell you very little about brain activity, which is the single most misunderstood point in this area.
What the research shows
The best human evidence for endogenous release is imaging. A positron emission tomography ligand-displacement study in ten trained athletes, scanned at rest and after two hours of endurance running, found euphoria ratings rose after running and were inversely correlated with opioid ligand binding in prefrontal and orbitofrontal cortices, anterior cingulate, bilateral insula and temporoparietal regions. This supports genuine central opioidergic activation during prolonged exercise, though ten participants is a small basis for a widely repeated claim. Naloxone-reversal studies of placebo analgesia point the same way, showing that expectation-driven pain relief depends on endogenous opioid signalling.
The negative and corrective findings matter as much. Plasma beta-endorphin rises with exercise and stress, but pituitary release does not equate to central action, and blood measurements have been repeatedly over-interpreted in the popular and supplement literature. Later work indicates endocannabinoid signalling contributes substantially to exercise-induced mood change, so the runner's high is not a purely endorphin phenomenon. There is no evidence that any oral product raises central beta-endorphin.
Evidence assessment
Limited evidence
Human data are physiological and imaging-based rather than therapeutic. The two human studies that survived audit are a ten-participant PET imaging study and an experimental pain study with naloxone blockade; neither administered beta-endorphin as a treatment. Historic intrathecal and intravenous administration exists only as small uncontrolled series. No modern controlled trial supports beta-endorphin as a treatment for anything.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Isolation and structure of an untriakontapeptide with opiate activity from camel pituitary glands Preclinical only
Original isolation and sequencing of the 31-residue beta-endorphin, identifying it as the C-terminal fragment of beta-lipotropin with potent opiate activity.
The runner's high: opioidergic mechanisms in the human brain Preclinical only
Euphoria increased after running and correlated inversely with opioid receptor ligand binding in frontolimbic regions, supporting central endogenous opioid release. Ten participants, no control group.
Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems Preclinical only
Expectation-driven placebo analgesia was reversed by naloxone, demonstrating that it depends on endogenous opioid signalling. Does not identify beta-endorphin specifically as the mediator.
Safety
Not used therapeutically. Administered exogenously it would carry the full mu-opioid risk profile: respiratory depression, sedation, nausea, constipation, tolerance and dependence. The peptide is destroyed by oral administration, so products claiming to deliver or boost beta-endorphin by mouth are not credible.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No UK marketing authorisation. Unlicensed substance. Its opioid pharmacology means any supply for human consumption raises questions under both the Human Medicines Regulations 2012 and controlled drug legislation. |
| United States | No FDA-approved beta-endorphin product. Supplied as a research reagent only. Note that it is an opioid agonist, and marketing it for human use would attract both FDA and DEA attention. |
| WADA (sport) | Not individually named on the Prohibited List. Prohibited at all times under section S0 as a non-approved substance; opioid agonists more broadly are prohibited in competition under section S7. |
Questions
No oral product has been shown to raise central beta-endorphin. The peptide is digested if swallowed, and blood levels do not reflect brain activity in any case. Claims to the contrary are marketing rather than evidence.
Only partly, and the evidence is thinner than the popular story suggests. One PET study in ten athletes does show central opioid release after prolonged running, but antagonist studies indicate endocannabinoid signalling also contributes.